Publications
Swiss Federal Supreme Court confirms validity of Bristol-Myers Squibb’s SPC for apixaban
Bristol-Myers Squibb successfully defended the Swiss SPC for the pharmaceutical active ingredient apixaban, used in the blockbuster anticoagulant Eliquis.- EN
Legal 500: Patent Litigation Comparative Guide
The Legal 500 Country Comparative Guides 2024, October 2024- EN
Patent Litigation 2024 Switzerland – Trends and Developments
Chambers and Partners, Global Practice Guides, Patent Litigation 2024, February 15, 2024- EN
The Legal 500 Country Comparative Guides 2023 – Switzerland: Patent Litigation
The Legal 500 Country Comparative Guides 2023, November 2023- EN
Patent Litigation 2023 Switzerland – Trends and Developments
Chambers and Partners, Global Practice Guides, Patent Litigation 2023, 01 March 2023- EN
- Simon Holzer
- Ulrike Ciesla
- Louisa Galbraith
- Simon Reuter
The Legal 500 Country Comparative Guides 2022 – Switzerland: Patent Litigation
The Legal 500 Country Comparative Guides 2022, November 2022- EN
Patent Litigation 2022 Switzerland – Trends and Developments
Chambers and Partners, Global Practice Guides, Patent Litigation 2022, 15 February 2022- EN
The Legal 500 Country Comparative Guides 2021 – Switzerland: Patent Litigation
The Legal 500 Country Comparative Guides 2021, November 2021- EN
Patent Litigation 2020 Switzerland – Trends and Developments
Chambers Patent Litigation 2021 Guide, 10 March 2021- EN
Does Switzerland need a new patent system with a fully examined patent, utility models and opposition proceedings?
Kluwer Patent Blog, 15 November 2020- EN
Switzerland: Patent Litigation
The Legal 500: Patent Litigation Country Comparative Guide, October 2020- EN
Patent Litigation 2020 Switzerland – Trends and Developments
Chambers Patent Litigation 2020 Guide, 10 February 2020- EN
